{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:14:11Z","timestamp":1788401651678,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-63598-6","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:37:35Z","timestamp":1759167455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunogenicity of fractional and standard dose COVID-19 vaccine boosters among healthy adults in Indonesia: twenty four month follow-up from a randomised controlled trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9637-7974","authenticated-orcid":false,"given":"John D.","family":"Hart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Fadlyana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-2775","authenticated-orcid":false,"given":"Nadia","family":"Mazarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Dwi","family":"Putri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-8271","authenticated-orcid":false,"given":"Kerryn A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor F. G.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djatnika","family":"Setiabudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6199-2125","authenticated-orcid":false,"given":"Muhammad Gilang Dwi","family":"Putra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0599-8645","authenticated-orcid":false,"given":"Cattram","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqila Sakina","family":"Zhafira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratama","family":"Wicaksana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwi","family":"Oktavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rini","family":"Fajarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-9767","authenticated-orcid":false,"given":"Agnes Rengga","family":"Indrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysanti","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-7815","authenticated-orcid":false,"given":"Yovita","family":"Hartantri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendarsyah","family":"Suryadinata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Sofiatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusnandi","family":"Rusmil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hindra I.","family":"Satari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Rezeki.","family":"Hadinegoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy B.","family":"Kartasasmita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julitasari","family":"Sundoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-6285","authenticated-orcid":false,"given":"Paul V.","family":"Licciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"von Mollendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward K.","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"63598_CR1","doi-asserted-by":"publisher","unstructured":"Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. https:\/\/doi.org\/10.1038\/s41579-022-00841-7 (2023).","DOI":"10.1038\/s41579-022-00841-7"},{"key":"63598_CR2","unstructured":"World Health Organization. COVID-19 Vaccine Tracker. Accessed 25 April 2025, https:\/\/covid19.trackvaccines.org\/agency\/who\/."},{"key":"63598_CR3","doi-asserted-by":"publisher","unstructured":"Fadlyana, E. et al. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in I. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(22)00800-3 (2023).","DOI":"10.1016\/S1473-3099(22)00800-3"},{"key":"63598_CR4","doi-asserted-by":"publisher","unstructured":"Munro, A. P. S. et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(21)02717-3 (2021).","DOI":"10.1016\/S0140-6736(21)02717-3"},{"key":"63598_CR5","unstructured":"World Health Organization. COVID-19 Vaccines with WHO Emergency Use Listing. Accessed 31 March 2023, https:\/\/extranet.who.int\/pqweb\/vaccines\/vaccinescovid-19-vaccine-eul-issued."},{"key":"63598_CR6","doi-asserted-by":"publisher","first-page":"103904","DOI":"10.1016\/j.ebiom.2022.103904","volume":"77","author":"Q Peng","year":"2022","unstructured":"Peng, Q. et al. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine 77, 103904 (2022).","journal-title":"EBioMedicine"},{"key":"63598_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijid.2022.03.028","volume":"119","author":"JL Suah","year":"2022","unstructured":"Suah, J. L. et al. Waning COVID-19 vaccine effectiveness for BNT162b2 and CoronaVac in Malaysia: an observational study. Int. J. Infect. Dis. 119, 69\u201376 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"63598_CR8","first-page":"100654","volume":"29","author":"CY Tan","year":"2022","unstructured":"Tan, C. Y. et al. Comparative effectiveness of 3 or 4 doses of mRNA and inactivated whole-virus vaccines against COVID-19 infection, hospitalization and severe outcomes among elderly in Singapore. Lancet Reg. Health West Pac. 29, 100654 (2022).","journal-title":"Lancet Reg. Health West Pac."},{"key":"63598_CR9","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","volume":"22","author":"ME McMenamin","year":"2022","unstructured":"McMenamin, M. E. et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect. Dis. 22, 1435\u20131443 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"63598_CR10","doi-asserted-by":"publisher","unstructured":"Costa Clemens, S. A. et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(22)00094-0 (2022).","DOI":"10.1016\/S0140-6736(22)00094-0"},{"key":"63598_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.7774\/cevr.2022.11.2.209","volume":"11","author":"T Santi","year":"2022","unstructured":"Santi, T. et al. Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia. Clin. Exp. Vaccin. Res. 11, 209 (2022).","journal-title":"Clin. Exp. Vaccin. Res."},{"key":"63598_CR12","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"63598_CR13","doi-asserted-by":"publisher","first-page":"106447","DOI":"10.1016\/j.jinf.2025.106447","volume":"90","author":"N Mazarakis","year":"2025","unstructured":"Mazarakis, N. et al. The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose. J. Infect. 90, 106447 (2025).","journal-title":"J. Infect."},{"key":"63598_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ijregi.2023.04.014","volume":"7","author":"M Boler","year":"2023","unstructured":"Boler, M. et al. Detection of SARS-CoV-2 antibodies after confirmed Omicron BA.1 and presumed BA.4\/5 infections using Abbott ARCHITECT and Panbio assays. IJID Reg. 7, 277\u2013280 (2023).","journal-title":"IJID Reg."},{"key":"63598_CR15","doi-asserted-by":"publisher","unstructured":"Lusvarghi, S. et al. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster\u2013elicited serum but evades most convalescent serum and therapeutic antibodies. Sci. Transl. Med. 14, https:\/\/doi.org\/10.1126\/scitranslmed.abn8543 (2022).","DOI":"10.1126\/scitranslmed.abn8543"},{"key":"63598_CR16","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.1016\/j.vaccine.2022.09.029","volume":"40","author":"B Liu","year":"2022","unstructured":"Liu, B., Gidding, H., Stepien, S., Cretikos, M. & Macartney, K. Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection. Vaccine 40, 6288\u20136294 (2022).","journal-title":"Vaccine"},{"key":"63598_CR17","first-page":"100953","volume":"42","author":"T Batmunkh","year":"2024","unstructured":"Batmunkh, T. et al. Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial. Lancet Reg. Health West Pac. 42, 100953 (2024).","journal-title":"Lancet Reg. Health West Pac."},{"key":"63598_CR18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJMc2215471","volume":"388","author":"DY Lin","year":"2023","unstructured":"Lin, D. Y. et al. Effectiveness of bivalent boosters against severe omicron infection. N. Engl. J. Med. 388, 764\u2013766 (2023).","journal-title":"N. Engl. J. Med."},{"key":"63598_CR19","unstructured":"World Health Organization. SAGE updates COVID-19 vaccination guidance 28 March 2023. Accessed 12 April 2023. https:\/\/www.who.int\/news\/item\/28-03-2023-sage-updates-covid-19-vaccination-guidance."},{"key":"63598_CR20","unstructured":"VIPER Group COVID-19 Vaccine Tracker Team. McGill University Interdisciplinary Initiative in Infection and Immunity. COVID-19 Vaccine Tracker. Accessed 3 July 2024, https:\/\/covid19.trackvaccines.org\/ (2024)."},{"key":"63598_CR21","unstructured":"Medicines and Healthcare Products Regulatory Agency. National Institute for Biological Standards and Control: WHO international standards. Accessed 31 March 2023, https:\/\/nibsc.org\/products\/brm_product_catalogue\/who_standards.aspx."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63598-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63598-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63598-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:37:43Z","timestamp":1759167463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63598-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63598"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63598-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.B.K., S.R.H., and J.S. are members of the Indonesian Technical Advisory Group on Immunisation. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8569"}}